Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017

Euro Surveill. 2017 Feb 9;22(6):30460. doi: 10.2807/1560-7917.ES.2017.22.6.30460.

Abstract

Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2016/17 influenza vaccine effectiveness (VE) against dominant influenza A(H3N2) viruses considered antigenically matched to the clade 3C.2a vaccine strain. Sequence analysis revealed substantial heterogeneity in emerging 3C.2a1 variants by province and over time. Adjusted VE was 42% (95% confidence interval: 18-59%) overall, with variation by province. Interim virological and VE findings reported here warrant further investigation to inform potential vaccine reformulation.

Keywords: effectiveness; influenza; influenza virus; influenza-like illness - ILI; vaccine-preventable diseases; vaccines and immunisation.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Canada / epidemiology
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Female
  • Hemagglutination Inhibition Tests
  • Humans
  • Infant
  • Influenza A Virus, H3N2 Subtype / genetics*
  • Influenza A Virus, H3N2 Subtype / immunology
  • Influenza A Virus, H3N2 Subtype / isolation & purification*
  • Influenza Vaccines / administration & dosage*
  • Influenza Vaccines / immunology
  • Influenza, Human / diagnosis
  • Influenza, Human / epidemiology
  • Influenza, Human / prevention & control*
  • Influenza, Human / virology
  • Middle Aged
  • Outcome Assessment, Health Care
  • Reverse Transcriptase Polymerase Chain Reaction
  • Seasons
  • Sentinel Surveillance
  • Sequence Analysis, DNA
  • Vaccination / statistics & numerical data
  • Vaccine Potency*
  • Young Adult

Substances

  • Influenza Vaccines